Prot #20170528: A Phase 1 First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

Project: Research project

Project Details

StatusFinished
Effective start/end date6/3/20 → 6/3/23

Funding

  • Amgen, Inc. (Prot #20170528)